GENEVA, Switzerland, July 1, 2026 /PRNewswire/ — MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced that the SwissNeuroRehab consortium has enrolled the first patients in a High-Dose, High-Intensity (HDHI) neurorehabilitation study. In parallel, MindMaze Therapeutics has launched the REACT-AVC study at Hospices Civils de Lyon, focused on early outpatient and home-based stroke rehabilitation. This progress marks a pivotal milestone in the Company’s strategy to consolidate its footprint in key European markets by obtaining reimbursement of at-home deployment.

Building on active partnerships with approximately 100 hospitals and care facilities across Europe, MindMaze Therapeutics is now focused on extending patient access into the home. The Swiss and French studies support this goal by laying the groundwork for at-home reimbursement, enabling the Company’s end-to-end solution suite to accompany patients throughout their full recovery journey, from inpatient care through outpatient rehabilitation and home.

MindMaze Therapeutics’ EU reimbursement strategy mirrors the model already established in the United States, where it holds CPT reimbursement codes for at-home utilization and has generated robust real-world evidence.

“Having established a strong reimbursement and real-world deployment foundation in the U.S., we are now extending that momentum into Europe” said Zach Henderson, CEO of MindMaze Therapeutics. “These studies in Switzerland and France reflect our commitment to making our neurotherapeutic platform accessible to patients across every stage of recovery, and to demonstrating the clinical and economic value of a truly integrated continuum of care.”

The SwissNeuroRehab-HDHI Study

SwissNeuroRehab (www.swissneurorehab.ch) is a CHF 11.2 million Innosuisse-backed national flagship consortium involving leading Swiss university hospitals, rehabilitation centers, and research, education, and industrial partners. Its mandate is to develop and validate technology-supported neurorehabilitation pathways across the continuum of care.

The SwissNeuroRehab study spans six major Swiss centers and covers the full continuum of care, encompassing inpatient, outpatient, and home-based rehabilitation phases. The study is a multicenter feasibility and implementation project evaluating whether HDHI neurorehabilitation can be delivered sustainably within a continuity-of-care framework. The study is powered by MindMaze’s precision neurotherapeutic platform and targets 300 minutes of active training per week, spanning a 4-6 week inpatient phase, an 8-12 week outpatient/home phase, and a follow-up at 15 months from inclusion.

Recruitment is active at Lausanne University Hospital (CHUV), Institution de Lavigny, Rehaklinik Valens, Swiss Rehabilitation Sàrl, Universitätsspital Zürich, and the Lake Lucerne Institute. The study is sponsored by the CHUV, funded within the Innosuisse Flagship Program, under the project SwissNeuroRehab, and registered on ClinicalTrials.gov (NCT07427511). For recruitment details, please refer to: [SwissNeuroRehab HDHI Study Flyer].

“SwissNeuroRehab brings together Switzerland’s leading rehabilitation institutions to rigorously evaluate HDHI therapy along the continuum of care. This is precisely the evidence base payers and policymakers need,” said Professor Andrea Serino, Coordinator of SwissNeuroRehab and Director of the Neurorehab Research Center, CHUV.

“Quantifying the impact of technology through this study has the potential to fundamentally reshape post-stroke recovery, extending to home, at scale, and sustainably reimbursed,” said Olivier Bill, MD, Principal Investigator, CHUV.

Expanding Across Europe: REACT-AVC and Neurorehab4EU

The SwissNeuroRehab HDHI study is part of a broader strategic European ambition. MindMaze Therapeutics is a core partner in Neurorehab4EU (https://www.neurorehab4.eu), a pan-European consortium spanning Switzerland, France, and Italy, designed to scale software enabled neurorehabilitation across European healthcare systems.

REACT-AVC, named after the French term for stroke (Accident Vasculaire Cérébral), is the consortium’s first clinical study, conducted at Hospices Civils de Lyon (HCL), one of France’s leading academic medical centers. Aligning with SwissNeuroRehab’s full-continuum design, REACT-AVC focuses on early outpatient and home-based rehabilitation for stroke patients, generating clinical and health-economic evidence to support reimbursement within the French healthcare system.

Together, SwissNeuroRehab and REACT-AVC represent MindMaze Therapeutics’ coordinated European evidence strategy, deployed across two healthcare systems, and designed to generate clinical and health-economic data each market’s payers require.

About MindMaze Therapeutics
MindMaze Therapeutics (SIX: MMTX) is a global leader in scalable, precision neurotherapeutics, dedicated to redefining the recovery trajectory for patients around the world. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to home-based therapy. The company’s FDA-listed and CE-marked products are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson’s disease, and other neurological disorders. With an extensive library of rigorous clinical validation and a robust R&D pipeline, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine. For more information, visit www.mindmazetherapeutics.com.

Media & Investor Contacts
Investor Relations:
Jeremy Meinen, Chief Financial Officer
ir@mindmazetherapeutics.com 

Media Inquiries:
VSC for MindMaze Therapeutics
mindmazetherapeutics@vsc.com 

DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as “believe,” “assume,” “expect,” “intend,” “may,” “could,” “will,” or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

View original content:https://www.prnewswire.com/news-releases/mindmaze-therapeutics-enrolls-first-patients-in-swissneurorehab-study-advancing-at-home-reimbursement-strategy-in-europe-302815404.html

SOURCE MindMaze Therapeutics Holding SA

Acquisition strengthens local manufacturing and logistics capabilities as REJURAN Cosmetics expands across Sephora, Amazon and Canada, with future growth across the Americas in view 

SEOUL, South Korea, July 1, 2026 /PRNewswire/ — PharmaResearch, the South Korea-based regenerative medicine company behind REJURAN, is strengthening its localization strategy across North America with the planned acquisition of Cosmetic Group USA, a U.S.-based cosmetics manufacturer also known as CG USA. 

PharmaResearch signed an agreement on June 30, local time, to acquire CG USA, a cosmetics OEM and ODM manufacturer, as demand for REJURAN Cosmetics continues to grow in the United States. 

Based in California, CG USA is a cosmetics OEM and ODM manufacturer with capabilities across product planning, formula development, manufacturing, filling, packaging, and quality control. The company holds a cosmetics manufacturing license and operates an FDA-registered facility with a quality management system aligned with current good manufacturing practice, or cGMP, standards. Its manufacturing infrastructure also supports production of over-the-counter (OTC) products. 

PharmaResearch decided to pursue the acquisition to respond more stably to growing demand for REJURAN Cosmetics, driven in part by its Sephora launch and expanding Amazon channel. Until now, the company has supplied the U.S. market with products manufactured in Korea. Through the acquisition of CG USA, PharmaResearch will secure a local manufacturing base, creating a foundation to improve supply chain efficiency and market responsiveness across production, logistics and distribution. 

Building on this, the company plans to strengthen supply stability in North America while accelerating its localization strategy across the Americas to support future expansion into Canada, broader North America and South America. 

REJURAN Cosmetics is PharmaResearch’s premium derma cosmetics brand, developed from the company’s regenerative medicine technology. Built around DOT™ c-PDRN®, the company’s patented cosmetic-grade PDRN ingredient, the brand has expanded its U.S. presence through online and offline retail channels, including Sephora and Amazon. REJURAN Cosmetics is also scheduled to enter Canada in the second half of the year, adding momentum to PharmaResearch’s broader North American expansion. 

“The acquisition of CG USA is a strategic decision to strengthen supply stability and build a stronger foundation for business expansion in North America,” said Ji Hoon Sohn, CEO of PharmaResearch. “Through this acquisition, PharmaResearch will secure a local production base to support its growth in North America, while also gaining the potential to expand its ODM business in the U.S. over the mid to long term.” 

Sohn added, “CG USA’s FDA-registered facility and OTC production capabilities make this acquisition meaningful not only for cosmetics, but also as a foundation for expanding into over-the-counter production. Based on local production capabilities and quality infrastructure, we will continue to strengthen the competitiveness of our global derma cosmetics business.” 

A CG USA representative said, “We are pleased to partner with PharmaResearch at an important stage in the growth of REJURAN Cosmetics. We look forward to supporting the brand’s expansion by bringing together CG USA’s manufacturing capabilities and PharmaResearch’s expertise.” 

Cosmo Group Inc. advised on the acquisition. Financial terms were not disclosed. 

About PharmaResearch: 

PharmaResearch is a pioneering biopharmaceutical company dedicated to enhancing the quality of life for humanity through regenerative medicine. Its diverse portfolio includes medicines, medical devices, cosmetics, and health supplements, all leveraging the core ingredients – DOT™ PDRN and DOT™ PN – which are protected by multiple patents. PharmaResearch is headquartered in Gangneung-si, Gangwon-do, South Korea, and has a U.S. subsidiary located in Costa Mesa, California, United States. 

Learn more at https://pharmaresearch.com/en/ 

About CG USA: 

CG USA, Cosmetic Group USA, is a Los Angeles-based cosmetics and personal care product development and manufacturing company founded in 1986. With a one-stop production system spanning research and development, manufacturing, filling and packaging, the company provides OEM and ODM services to global brands. CG USA operates an FDA-registered facility and holds ISO 22716 certification. Based on a quality management system aligned with cGMP standards, the company has the manufacturing capabilities to produce over-the-counter, or OTC, products. 

*cGMP: A pharmaceutical manufacturing and quality management system that complies with U.S. FDA regulations. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/pharmaresearch-accelerates-rejuran-cosmetics-expansion-across-north-and-south-america-with-planned-acquisition-of-cg-usa-302815417.html

SOURCE PharmaResearch

HYDERABAD, India, July 1, 2026 /PRNewswire/ — ICFAI Business School (IBS) opened the registration process for IBSAT 2026 starting July 1st, 2026. The national-level entrance exam to join the nine IBS campuses’ two-year, full-time MBA and PGPM programs.

Aspiring management candidates can apply online through a single application with a fee of INR 1,800.

IBSAT – A Student-Friendly MBA Entrance Exam

IBSAT 2026 will be conducted as a 2-hour, online, home-proctored test. Candidates can comfortably take the test from their homes.

The test comprises 140 Multiple Choice Questions (MCQs) from four sections:

Verbal Ability: 50 questionsReading Comprehension: 30 questionsQuantitative Aptitude: 30 questionsData Adequacy & Interpretation: 30 questions

In the test, there is no negative marking and no sectional time limits, allowing candidates to freely navigate between sections.

INR 10 Crore Scholarships:

To support meritorious students and promote inclusivity, ICFAI Business School has announced 500 scholarships worth Rs 2 Lakh each. These are accessible to top scorers in IBSAT 2026, as well as high achievers in CAT, XAT, GMAT™, and NMAT by GMAC™. Special scholarship provisions are also extended to the wards of IBS alumni, wards of Defence Personnel (in-service/retired) from the Army, Air Force, Navy, and Paramilitary Forces, and physically challenged candidates.

Admission Timeline

Following the IBSAT exam in December 2026, shortlisted candidates will clear a centralized selection process at IBS Hyderabad in February 2027, featuring a micro-presentation and personal interview. ICFAI Business School also accepts valid scores from CAT, XAT, NMAT by GMAC™, and GMAT™ (2024 onwards).

Interested aspirants can register on the official institutional portal starting July 1st, 2026. To know more, please visit www.ibsindia.org

Bridging Theory and Corporate Reality

The campuses in Bengaluru, Dehradun, Hyderabad, and Jaipur offer full-time MBA degrees, while the Ahmedabad, Gurugram, Kolkata, Mumbai, and Pune campuses provide full-time PGPM programs.

ICFAI Business School emphasizes a 100% case-based learning model. This approach replicates real-world corporate challenges directly inside the classroom. Leading this academic standard is the AACSB-accredited IBS Hyderabad campus, which features an in-house Case Research Center (CRC) ranked 3rd globally in The Case Centre’s Case Impact Index, 2025.

To make graduates entirely industry-ready, the curriculum integrates a mandatory 14-week summer internship alongside certificate access to Bloomberg and SAP labs. The institution also prides itself on an inclusive academic environment, maintaining a balanced 50% gender diversity across all campuses.

Consistent Placement Performance

Corporate trust in ICFAI Business School remains exceptionally strong, as evidenced by the placement outcomes for the Class of 2026. All nine campuses recorded placements above 90%, with the highest CTC at Rs 40 LPA.

For IBS Hyderabad, the CTC is INR 15.58 LPA for the top 10% and INR 13.36 LPA for the top 25%, underscoring strong market demand for its corporate-ready graduates.

Contact Information:
IBS Admission Office
Plot No. 65, Nagarjuna Hills
Punjagutta, Hyderabad – 500082
Telangana.
Ph: 040 – 23440963 (5 lines)
Toll Free :1800 425 55 66 77
E-mail: ibsat@ibsindia.org 

Photo: https://mma.prnewswire.com/media/3002846/IBSAT_MBA_Entrance_Test.jpg
Logo: https://mma.prnewswire.com/media/1023356/6019645/IBS_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/icfai-business-school-opens-ibsat-2026-registrations-announces-10-crore-scholarship-program-302815427.html